Trends in Mental Health Technology

The American Psychological Association’s new Health Advisory on chatbots and wellness apps feels like a real turning point in how we think about technology’s role in mental health. Millions are already turning to general-purpose AI tools like ChatGPT for emotional support. Yet most of these models weren’t built for mental health, and their risks, especially for vulnerable users, are becoming harder to ignore. As a psychologist, I’m glad to see the APA calling this out: AI is not neutral in mental health. It can support healing, but it can also deepen distress if used irresponsibly. Rethinking mental health means rethinking entry points. Subclinical support can catch people before they fall, and ensure clinical care is available for those who need it most. What’s needed now: ✅ Clear lines between wellness tools and clinical interventions ✅ Harm reduction built into design, not bolted on later ✅ Provider training to safely guide clients who are already bringing AI into the therapy room ✅ Transparency, labeling, and escalation pathways baked into every layer ✅ Deep attention to vulnerable populations such as youth, those with obsessive or disordered thinking, and socially isolated users, to ensure AI responses are supportive – not contraindicated At Headspace, these ideas are already core to how we build: 🔍 Transparency & Labeling: AI companions like Ebb clearly communicate they’re not therapists, and connect people to human support when needed. 🧠 Safety-by-Design: Continuous monitoring for risk, crisis escalation pathways, and design choices that encourage human connection, not replace it. 🤝 Human Oversight & Accountability: Clinicians and researchers are embedded in the development process to ensure that what we build is evidence-based, ethical, and genuinely supportive. The APA is right: Regulation must evolve. It must be strong enough to safeguard, flexible enough to enable responsible innovation. If we get this right, AI won’t widen the care gap. It will close it. https://lnkd.in/gWDzZyMU Would love to hear your take👇

🧠 Neurotech Network 🧠 For sixty years the default answer to depression has been a pill. What is changing now is not just the science. It is the range of technologies we are using to interact with the brain. In the last eighteen months we have seen major regulatory approvals for at-home neurotech, rapid advances in TMS protocols, early clinical work in focused ultrasound, and the first wave of neural interface companies exploring psychiatric applications. This is not one technology replacing medication. It is the emergence of an ecosystem. In my latest piece I map the companies and modalities building that ecosystem, from tDCS and TMS to focused ultrasound, neural interfaces and photobiomodulation. At the end of the article I also included a technology taxonomy of mental health neurotech outlining the key modalities and the companies building them. If you are building, investing in, or following neurotechnology, this landscape is evolving quickly and worth paying attention to. https://lnkd.in/edSR7XTa #Neurotechnology #MentalHealth #Neuromodulation #BCI #BrainHealth Flow Neuroscience Neurolief Ampa Magnus Medical Neuronetics, Inc. BrainsWay Motif Neurotech Inner Cosmos INBRAIN Neuroelectronics Magstim Syntropic Attune Neurosciences, Inc. Vielight Inc. Nudge Merge Labs Nexstim

𝐌𝐞𝐧𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 (𝐃𝐓𝐱) 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 The current landscape of digital therapeutics (DTx) for mental health illustrates a significant transformation in how mental health conditions are treated, with a focus on innovative, accessible, and personalized care. Personalization and Customization A major trend across DTx products is the emphasis on personalized treatments tailored to individual needs. Advanced technologies such AI, VR, and real-time biometric data are employed to adapt therapies based on personal health patterns and responses. Increased Accessibility and Convenience DTx products leverage mobile and web applications to make mental health care more accessible. This is crucial in reducing barriers to accessing therapy, such as stigma or geographical limitations. Companies like SilverCloud® and BeMe Health provide therapeutic interventions directly to users’ devices, allowing for private and convenient access to mental health care, which can be particularly appealing to those reluctant to engage in traditional therapy settings. Gamification and Engaging Content To enhance engagement and adherence, many DTx companies incorporate gamification and interactive elements into their therapies. This approach, utilized by companies like BFB Labs and Arcade Therapeutics, makes treatment more appealing, especially to younger demographics who might find game-based interventions more engaging than conventional therapies. Focus on Regulatory Compliance and Clinical Validation As the DTx field matures, companies are increasingly focusing on obtaining regulatory approvals and validating their solutions through clinical trials. This not only ensures the efficacy and safety of digital therapies but also helps in building trust among users and healthcare providers. Companies like Click Therapeutics, Inc. and Big Health are at the forefront, conducting rigorous studies to secure FDA approval for their products. Technological Innovations Innovation in technology is a hallmark of the DTx sector, with companies utilizing VR, AI, and other advanced technologies to create more immersive and effective therapeutic experiences. This is evident in the work of companies like XRHealth (formerly Amelia), which uses VR to simulate therapeutic scenarios that help patients manage conditions like anxiety and PTSD in a controlled environment. The DTx sector represents a progressive shift in mental health care, emphasizing patient-centered approaches that harness technological advancements to improve accessibility, personalize care, and enhance patient engagement. This dynamic field continues to evolve, promising to reshape mental health practices with innovative solutions that bridge the gap between technology and traditional care. #MentalHealth #DigitalTherapeutics #DTx #DigitalHealth

Another clear shift we’re seeing across the nearly 500 mental health companies we’re tracking at Bezyl®: A move toward more objective and precise data. For decades, mental health has relied heavily on subjective reporting: How do you feel? How have you been this week? These questions are still important. But they don’t tell the full story. We’re now seeing a growing number of solutions beginning to incorporate: ·     Biometric signals (heart rate, sleep, nervous system activity) ·     Passive behavioral data (patterns over time, not just moments in time) ·     Real-world inputs that provide more continuous insight This isn’t about replacing human experience. It’s about adding another layer of understanding. Because mental health is dynamic, and what we capture in a single moment doesn’t always reflect what’s actually happening over time. We’re seeing this take shape in different ways across the ecosystem: Eye Minders → The eyes are a powerful interface to the brain, reflecting both mental effort and emotional state. Eye Minders is studying diagnostic approaches that could enable more precise detection of mood, stress, depression, and even PTSD. Appscent Medical → Developed SCENTIFIC, A Class II medical device designed to support relaxation through contactless, scent-based biofeedback. Using radar-based respiratory sensing and olfactory cues, the system monitors breathing patterns and gently guides awareness during rest and sleep. Reflect Innovation → Developed an orb that helps individuals track and regulate stress in real time. By simply holding it, users can see their physiological state shift as the orb responds from stress to calm. Equanimity AI → Developed Beacon, an operating system currently used to monitor pain between patient visits, with plans to extend this personalized diagnostic approach into mental wellness and broader therapeutic applications. Different approaches. Same underlying shift. This shift has the potential to: ·     Improve how we understand mental states ·     Enable more personalized support ·     And help identify changes earlier and more accurately But it also raises important questions: ·     How do we interpret these data responsibly? ·     How do we ensure privacy and trust? ·     And how do we integrate it into care in a meaningful way? This is still an emerging area, but it’s one that will play a critical role in how mental health evolves. We’ll continue to highlight more companies building in this space as we move forward. Sign up for early access to our global mental health map coming soon! https://bezyl.com/contact/ Daphna Palti-Wasserman Erez Levanon Noga Sapir Yosi A.

Most mental-health startups aren’t fundable, but the opportunity is still huge. Every month, if not week, another mental-health startup deck lands in my inbox. The problem is huge, their missions are admirable, but most are built on a model that simply doesn’t work anymore. The issue isn’t with demand. It’s retention and user economics. The global mental-health app market is booming toward $15 billion, yet I’ve read that more than 90% of users drop off within 30 days. Six-month retention? Below 4% (worse than dating apps). When users vanish that fast, the economics get ugly. Customer acquisition costs are sky-high and lifetime value never catches up. Even Calm and Headspace, the giants of the category, struggle to make the numbers work. Add in a crowded field, little clinical validation, and no real defensibility and most of these decks are unfortunately a non-starter for investors. Where is real opportunity? Interesting work is happening in regulated, prescription digital therapeutics (DTx). This is software prescribed by clinicians, often reimbursed by payers, and backed by clinical evidence. These products can show real results: 20–35 % reductions in depression and anxiety symptoms, with 60–80 % program completion rates. They sit within care pathways, not app-store churn. And their business models, built around reimbursement and regulatory clearance, are far more defensible. This approach is definitely harder, slower, and more clinical - but it can work. It’s these elements that make the opportunities more investable. Mental-health tech can still get funding, but investors now care less about downloads, and more about evidence and outcomes.

Why are millions abandoning professional mental health apps for simple AI chatbots? Despite 20,000+ apps on the market, users are abandoning them in days – often turning to raw GenAI like ChatGPT for emotional support. This isn't just a trend; it's a critical shift with serious implications for mental health care. In my latest article, I unpack why even well-designed apps are quickly 'ghosted', failing to retain users, and explore the alarming rise of unregulated AI in mental health. More importantly, I propose how mental health professionals and app developers can collaborate to build truly effective, human-centered digital healing spaces. This is a must-read for anyone serious about the future of digital mental health. #MentalHealthTech #DigitalTherapeutics #HealthcareInnovation #UXDesign #MentalWellness #ChatGPT #LLMs #DigitalMentalHealth

At the start of every year, I like to pause and think about what’s coming next. If 2025 was about momentum, 2026 will be about convergence. Here's what I expect will define mental health innovation over the next 12 months: 🔶 Sleep will take center stage  Advances in narcolepsy treatment are on the horizon, potentially the biggest in a generation. What many people miss is how deeply sleep disorders connect to psychiatric conditions, including depression, anxiety, and substance use. Our platform tracks these intersections in ways traditional research cannot. 🔶 Alternative therapies will gain traction The regulatory environment is shifting toward greater openness for novel approaches, including psychedelics. Whatever your view on these treatments, we need rigorous data on how patients actually respond. That's where Holmusk comes in. 🔶 Tech giants will need healthcare data partners Companies like OpenAI and Anthropic are considering the way their products can affect users’ mental health and have begun building guardrails to handle sensitive conversations. Their models need training data that reflects clinical reality, not internet chatter. We've spent 10 years curating exactly that. The third trend excites me most. For the first time, I see genuine potential in partnerships with AI-native companies rather than traditional healthcare incumbents. They move fast. They think differently. And they understand that data quality determines everything. The decade ahead will bring more change to mental health than the previous 50 years combined. My job is to make sure Holmusk is the infrastructure that makes that change possible. We're not waiting for the future. We're building it.

Many innovations of psychotherapies are currently examined. In our recent paper in World Psychiatry, we present an overview of the most important innovations and the supportive evidence. There are 4 domains of innovation: (1) Digital interventions (Internet-based and mobile interventions; serious games; virtual and augmented reality; prescription digital therapeutics; blended therapy; avatar therapy; chatbots/AI generated conversational agents) (2) Personalized treatments (research on predictors/moderators in large RCTs; ‘individual patient data’ (network) meta-analyses; machine learning approaches; personalised and modular therapies; matching therapists to patients) (3) New and improved therapies (cognitive bias modification; cognitive remediation; psychedelic-assisted psychotherapy; transdiagnostic therapies; research on effective components through factorial trials; component network meta-analyses; etc);  (4) Dissemination and simplification of therapies (digital interventions in LMICs; task sharing interventions; single session interventions). The empirical support for the innovations varies considerably, from dozens of  supporting trials to few or none. None of them will be a paradigm-shifting “silver bullet” that dramatically increases outcomes. Progress is only possible through multiple, incremental improvements. With Mathias Harrer, Toshi Furukawa https://lnkd.in/eHRQdq3m

On Tuesday, I shared what stood out to me in 2025. Today, I'm focusing on 2026, which could be a pivotal year in psychiatry. Based on coverage from MDLinx, Psychiatric Times, National Institute of Mental Health (NIMH), and the American Medical Association (AMA), here are the trends I’m watching most closely: 1. Permanent telehealth flexibilities, including home-based care and appropriate audio-only options 2. Digital biomarkers and AI to predict relapse and personalize treatment 3. AI-assisted psychological assessment tools entering routine practice 4. Virtual and hybrid clinical trials that expand access to research 5. Advances in neuromodulation, including next-generation and accelerated TMS protocols 6. New treatment modalities in pharmacology, including rapid-acting and mechanism-novel agents 7. Wider adoption of measurement-based care as a standard of practice 8. Clearer ethical and safety frameworks for AI in mental health 9. Innovative workforce models to address psychiatrist shortages 10. Stronger focus on access, equity, and value-based behavioral health care In short: psychiatry is moving toward care that is more precise, more accessible, and more patient-centered.

Top 7 AI Mental Health Startups  that recently got funded 1. Spring Health: Raised $100M Series E Uses AI to match people quickly with the right therapy or care plan, making mental health support hyper-personalized and accessible at scale. 2. Headway: Raised $100M Series D An AI and platform solution that connects users to therapists who accept insurance, so more people can afford professional mental health help. 3. Grow Therapy: Raised $88M Series C Empowers therapists to start private practices, while using AI to match people to the right therapy and expand insurance-covered care across the U.S. 4. Ellipsis Health: Raised $45M Series A Analyzes voice and speech with AI to quickly detect signs of stress, anxiety, and depression, helping providers offer timely support. 5. Oliva: Raised $5.4M Offers on-demand workplace mental health support with AI-powered screening, connecting employees with therapists and tailored resources. 6. manatee: Raised $1.5M Seed Uses a fun, AI-powered app for kids and families to teach emotional regulation and resilience, supporting therapy through gamified, daily engagement. 7. Mightier: Raised $17 million in Series B Uses video games backed by clinical research to help children learn how to control their emotions. Few patterns I observed: > Largest funding is going to platforms solving access and scale, making care easier to find and afford. > There is strong investor interest in AI tools for quick, personalized intervention, especially matching to therapy or fast symptom detection. > AI is used for rapid, personalized intervention, voice, chatbots, matching algorithms and not just basic automation. > Niche and youth-focused solutions (kids, families, workplaces) are getting small targeted funding. The market may be smaller, but the emphasis is now also on solving specific problems of specific groups. > Investors are rewarding companies with clinical validation and strong networks, not just flashy tech.